Short answer
ARTIVION, INC. (AORT) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $116M (up 17.5% year over year) with net income of $1M.
Q1 2026 key financials · XBRL
- Revenue
- $116M
- +17.5% YoY
- Net income
- $1M
- +380.6% YoY
- Operating margin
- 5.0%
- Gross margin
- 64.9%
- EPS (diluted)
- $0.03
- +400.0% YoY
Source: XBRL data from the ARTIVION, INC. (AORT) Q1 2026 10-Q on SEC EDGAR. USD.
ARTIVION, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $116.3M, up 18% YoY from $99.0M; constant-currency revenue up 12%
- Gross margin 65% vs 64% YoY; G&A and marketing 52% of revenue vs 55%
- Best segment preservation services $24.9M, up 23%; worst other products $2.3M, down 9%
- Operating cash flow $1.2M vs $(17.0)M YoY; investing cash outflow $10.5M vs $3.6M
- Cash $55.8M; $220.0M total principal indebtedness and $150.0M delayed-draw facility borrowing in May 2026
- Near-term headwinds: currency volatility, seasonal demand, tissue availability, competing products and potential financing needs
Risk Factors
- Italian medical-device payback exposure, estimated at approximately $2.3 million for 2019–2025
- Endospan acquisition adds sole-source manufacturing dependence in Herzliya, Israel amid Iran conflict-related disruption risk
- Draft FDA tuberculosis guidance could significantly reduce safe donated-tissue supply if implemented as written
- Intensifying competition from larger medical-device companies threatens pricing, adoption, and financial results
- Foreign-currency exposure concentrated in Euro-denominated revenues and balances relative to the US Dollar
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARTIVION, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.